International Stem Cell Corporation
(OTCBB:ISCO)

International Stem Cell Corporation (OTCBB:ISCO) develops a powerful new stem cell technology called “parthenogenesis” that promises to significantly advance the field of regenerative medicine by addressing the significant problem of immune-rejection. Parthenogenesis utilizes unfertilized human eggs to create “parthenogenetic” stem cells (hpSC) that can be “immune-matched” to millions of persons of differing sexes and racial backgrounds. A relatively small number of hpSC lines could provide sufficient immune-matched cells to cover large parts of the world’s population. ISCO plans to create a bank of these valuable hpSC lines (UniStemCell™) to serve all populations across the world.

Human parthenogenetic stem cells have great therapeutic potential, yet do not require viable human embryos, thus avoiding ethical issues. ISCO’s scientists are focused on using hpSC to treat severe diseases of the eye, the nervous system and the liver where cell therapy has been proven clinically yet is limited by the availability of safe immune-matched human cells.

November 16, 2011:
International Stem Cell to Hold Business Update Conference Call on November 17. Click here for call recording.

September 12, 2011:
Use the link below to access the International Stem Cell Corporation presentation by Kenneth Aldrich, Chairman, at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 12, 2011 at 11:40 a.m. Eastern (8:40 a.m. Pacific). The conference takes place at the Waldorf Astoria Hotel in New York City.

August 2011:
Click here to watch a brief, informative interview, International Stem Cell’s Chairman Kenneth Aldrich discusses the Company’s scientific and medical breakthroughs, therapeutic potential, and business plans.

ISCO advances and operates three businesses.